Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents
- 458 Downloads
The aim was to compare the efficacy between doublets of third-generation agents (non-platinum) and doublets of platinum plus a third-generation agent (platinum-based) for chemotherapy-naïve advanced non-small-cell lung cancer (NSCLC).
We conducted a literature-based meta-analysis to compare the efficacy between doublets of third-generation agents and doublets of platinum plus a third-generation agent for chemotherapy-naïve advanced NSCLC. The primary end point was overall survival, and the secondary end points were progression-free survival (PFS) and response rate. Subgroup analyses were also conducted by different non-platinum doublet regimens or different platinum-based doublets. A descriptive review for toxicity was performed.
Sixteen randomized controlled trials were identified ultimately. Results demonstrated that the efficacy of non-platinum doublets was comparable with platinum-based doublets according to the overall survival (HR = 1.03, 95 % CI = 0.98–1.08, p = 0.29). Subgroup analyses by different non-platinum doublets also showed the efficacy of all the third-generation doublets, such as vinorelbine plus gemcitabine, vinorelbine plus paclitaxel, gemcitabine plus paclitaxel, and gemcitabine plus docetaxel, was comparable with platinum-based doublets (HR = 1.00, 95 % CI = 0.78–1.27, p = 0.98; HR = 0.97, 95 % CI = 0.80–1.18, p = 0.79; HR = 1.05, 95 % CI = 0.99–1.12, p = 0.11; HR = 1.01, 95 % CI = 0.92–1.10, p = 0.87; respectively). Subgroup analyses by different platinum-based doublets indicated that the efficacy of the third-generation doublets were equal to both cisplatin-based doublets and carboplatin-based doublets (HR = 1.08, 95 % CI = 1.00–1.17, p = 0.05; HR = 1.00, 95 % CI = 0.94–1.05, p = 0.94; respectively). The secondary end points indicated that platinum-based doublets might have an advantage in PFS but not in response rate (HR = 1.06, 95 % CI = 1.01–1.12, p = 0.03; RR = 0.99, 95 % CI = 0.90–1.08, p = 0.81; respectively).
Non-platinum doublets were as effective as platinum-based doublets with different toxicity profile for chemotherapy-naïve advanced NSCLC in the era of third-generation agents.
KeywordsCarcinoma Non-small-cell lung Chemotherapy Platinum Third-generation agents Meta-analysis
- Barata FJ, Parente B, Cunha J, Fernandes A, Figueiredo A, Conde S et al (2002) A phase II study, multicenter, randomized of carboplatin plus gemcitabine (CG) versus vinorelbine plus gemcitabine (VG) in advanced non small cell lung cancer (NSCLC) [abstract]. ESMO annual meeting. 523 pGoogle Scholar
- Chen YM, Perng RP, Lee YC, Shih JF, Lee CS, Tsai CM et al (2002) Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol 13:108–115PubMedCrossRefGoogle Scholar
- Fløtten Ø, Bremnes RM, Grønberg BH, Sundstrøm S, Amundsen T, Rolke H et al (2010) Phase III study comparing vinorelbine/gemcitabine with vinorelbine/carboplatin as first-line chemotherapy of advanced NSCLC: a Norwegian Lung Cancer Study Group trial [abstract]. J Clin Oncol 15(suppl): abstr 7597Google Scholar
- Galvez C, Galmarini F (2000) Gemcitabine/cisplatin (G/P) vs gemcitabine/vinorelbine (G/V) in the treatment of non-small cell lung cancer (NSCLC): stage IIIB and IV abstract]. Ann Oncol 11(suppl 4):S115 (abstr 526P)Google Scholar
- Gamaz M, Taright TMS (2006) Gemcitabine/docetaxel (GD) versus gemcitabine/cisplatin (GC) in stage III/IV non-small cell lung cancer (NSCLC): preliminary results [abstract]. ASCO Annual Meeting Proceedings Part I 24(18S): abstr 17116Google Scholar
- Georgoulias V, Samonis G, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A et al (2001a) Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 34(Suppl 4):S47–S51PubMedCrossRefGoogle Scholar
- Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF et al (2003) Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3025–3034PubMedCrossRefGoogle Scholar
- Iwamoto Y, Saito H, Nakagawa K, Kashii T, Katakami N, Nakano T, et al (2007) A randomized phase II study of carboplatin and paclitaxel (CP) versus gemcitabine and vinorelbine (GV) in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): West Japan Thoracic Oncology Group 00 [abstract]. ASCO Annual Meeting Proceedings Part I 25(18S): abstr 18060Google Scholar
- Julian PTH, Douglas GA, Jonathan ACS (updated March 2011) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0. http://www.cochrane-handbook.org. Accessed 10 Feb 2012
- Katakami N, Takiguchi Y, Yoshimori K, Isobe H, Bessho A, Yoshimura A et al (2006) Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. J Thorac Oncol 1:447–453PubMedCrossRefGoogle Scholar
- Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D et al (2008) Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 19:115–122PubMedCrossRefGoogle Scholar
- Rigas JR, Carey M, Dragnev KH, Simeone SA, Page RD, Rubin MS et al (2008) Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): subgroup analysis from D0112 [abstract]. J Clin Oncol 26(15suppl): abstr 8100Google Scholar
- Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F et al (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975. J Clin Oncol 21:3909–3917PubMedCrossRefGoogle Scholar
- Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB, Marinucci DM et al (2010) A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol 21:540–547PubMedCrossRefGoogle Scholar
- Walling J (1994) Chemotherapy for advanced non-small-cell lung cancer. Respir Med 88(649–657):18Google Scholar
- Yamamoto N, Nakagawa K, Uejima H, Sugiura T, Takada Y, Negoro S et al (2006) West Japan Thoracic Oncology Group (WJTOG). Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104. Cancer 107:599–605PubMedCrossRefGoogle Scholar